Partnering Door Opens For Sarepta With 48-Week Data In Hand
This article was originally published in The Pink Sheet Daily
Executive Summary
Sarepta Therapeutics’ positive data on its lead muscular dystrophy drug eteplirsen puts the company in a strong position at the partnering table and sets the stage for a neck and neck race with GSK/Prosensa to bring the first treatment for the rare disease to market.
You may also be interested in...
DMD Drugs Take Center-stage As Sarepta Waits On Accelerated Approval Go/No-Go
New data from GSK and Prosensa has Sarepta investors eager for news on the future of its drug as competition heats up in the rare disease space.
$118 Million Offering Should Position Sarepta Strongly For Partnering Talks
As the Duchenne muscular dystrophy-focused biotech raises significant cash from institutional investors, CEO clarifies that Sarepta is intent on finding the right partner, structure and economics for an ex-North American opportunity.
Sarepta’s Eteplirsen and FDA’s “Breakthrough Therapy” Designation: A Perfect Fit?
Strong early efficacy data for Sarepta’s Duchenne therapy has investors speculating about whether the drug can qualify for accelerated approval. But maybe the first step should be use of the new FDA “Breakthrough” designation.